Abstract:You have accessJournal of UrologyCME1 Apr 2023PD10-08 THE PROGNOSTIC IMPACT OF PREOPERATIVE PSMA-PET ON EARLY ONCOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS TREATED WITH RADICAL PROSTATECTOMY: RESULTS OF A MULTI-CENTER ANALYSIS Simone Scuderi, Giorgio Gandaglia, Armando Stabile, Armando Stabile, Elio Mazzone, Francesco Barletta, Nicolai Huebner, Eugenio Brunocilla, Agostino Mattei, Luca Afferi, Shahrok Shariat, Giancarlo Marra, Junlong Zhuang, Hongqian Guo, Riccardo Schiavina, Lorenzo Bianchi, Fabio Zattoni, Giuseppe Reitano, Pawel Rajwa, Juan Gomez Rivas, Claudia Kesch, Enrico Checcucci, Francesco Porpiglia, Edoardo Cisero, Daniele Amparore, Maria Picchio, Francesco Montorsi, and Alberto Briganti Simone ScuderiSimone Scuderi More articles by this author , Giorgio GandagliaGiorgio Gandaglia More articles by this author , Armando StabileArmando Stabile More articles by this author , Armando StabileArmando Stabile More articles by this author , Elio MazzoneElio Mazzone More articles by this author , Francesco BarlettaFrancesco Barletta More articles by this author , Nicolai HuebnerNicolai Huebner More articles by this author , Eugenio BrunocillaEugenio Brunocilla More articles by this author , Agostino MatteiAgostino Mattei More articles by this author , Luca AfferiLuca Afferi More articles by this author , Shahrok ShariatShahrok Shariat More articles by this author , Giancarlo MarraGiancarlo Marra More articles by this author , Junlong ZhuangJunlong Zhuang More articles by this author , Hongqian GuoHongqian Guo More articles by this author , Riccardo SchiavinaRiccardo Schiavina More articles by this author , Lorenzo BianchiLorenzo Bianchi More articles by this author , Fabio ZattoniFabio Zattoni More articles by this author , Giuseppe ReitanoGiuseppe Reitano More articles by this author , Pawel RajwaPawel Rajwa More articles by this author , Juan Gomez RivasJuan Gomez Rivas More articles by this author , Claudia KeschClaudia Kesch More articles by this author , Enrico CheccucciEnrico Checcucci More articles by this author , Francesco PorpigliaFrancesco Porpiglia More articles by this author , Edoardo CiseroEdoardo Cisero More articles by this author , Daniele AmparoreDaniele Amparore More articles by this author , Maria PicchioMaria Picchio More articles by this author , Francesco MontorsiFrancesco Montorsi More articles by this author , and Alberto BrigantiAlberto Briganti More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003250.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: PSMA-PET in prostate cancer (PCa) staging is associated with higher accuracy for nodal and metastatic detection than conventional imaging. Clinical guidelines still do not recommend PSMA-PET before radical prostatectomy (RP). We hypothesized that the implementation of PSMA PET in the preoperative staging pathway is associated with better patient risk stratification and early cancer control. METHODS: We relied on 3,978 N0M0 PCa patients treated with RP +/- extended pelvic nodal dissection between 2010 and 2022. 3,518 men staged with conventional imaging were identified in a single institution dataset (Group 1). Additional 278 patients with available details both on PSMA PET and CT scans were identified from a multi-institutional cohort of men staged with PSMA-PET (Group 2). Early recurrence was defined as PSA persistence (first postoperative PSA ≥0.1 ng/ml) or PSA rise ≥0.2 ng/ml within 1 year after RP. Multivariable logistic regressions (MLR) tested the impact of the preoperative imaging on early recurrence. MLR models tested for predictor status of PET-PSMA and CT-scan after adjusting for PSA, biopsy grade group and non-organ-confined (NOC) disease at mpMRI. Accuracy of MLR models containing PET-PSMA (model 1) and CT-scan (model 2) were assessed with the ROC-derived AUC. Decision-curve analyses (DCA) assessed the net benefit associated with the use of the two models. RESULTS: 282 patients experienced early recurrence. Patients in Group 2 had higher preoperative PSA values (8.5 vs. 6.4 ng/mL) and higher rates of biopsy grade group (GG) >3 (57% vs. 11%, all p<0.01) compared to Group 1. Early BCR rates were similar between the two groups (12% vs. 10% for group 2 and group 1, respectively, p=0.3). At MLR, being staged with PSMA-PET was associated with a lower risk of early recurrence (OR 0.61, p=0.01) after accounting for PSA, clinical stage, and biopsy ISUP GG. Focusing on men with available PSMA-PET and CT, the presence of positive PET-PSMA (OR: 4.34, p=0.004) but not CT-scan predicted early recurrence. The discrimination was higher for model 1 including PSMA-PET compared to model 2 (73 vs 67%). The adoption of model 1 including PSMA-PET was associated with a higher net benefit as compared to model 2. CONCLUSIONS: Non-metastatic PCa patients staged with PSMA PET scan are at lower risk of early recurrence when compared to those staged with conventional imaging alone. PSMA PET scan helps clinicians to improve preoperative risk stratification and to the identification of men who might benefit most from treatments. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e329 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Simone Scuderi More articles by this author Giorgio Gandaglia More articles by this author Armando Stabile More articles by this author Armando Stabile More articles by this author Elio Mazzone More articles by this author Francesco Barletta More articles by this author Nicolai Huebner More articles by this author Eugenio Brunocilla More articles by this author Agostino Mattei More articles by this author Luca Afferi More articles by this author Shahrok Shariat More articles by this author Giancarlo Marra More articles by this author Junlong Zhuang More articles by this author Hongqian Guo More articles by this author Riccardo Schiavina More articles by this author Lorenzo Bianchi More articles by this author Fabio Zattoni More articles by this author Giuseppe Reitano More articles by this author Pawel Rajwa More articles by this author Juan Gomez Rivas More articles by this author Claudia Kesch More articles by this author Enrico Checcucci More articles by this author Francesco Porpiglia More articles by this author Edoardo Cisero More articles by this author Daniele Amparore More articles by this author Maria Picchio More articles by this author Francesco Montorsi More articles by this author Alberto Briganti More articles by this author Expand All Advertisement PDF downloadLoading ...

The More You See the More You Miss. PSMA PET/CT is Still Affected by a Substantial Risk of Underestimation in Prostate Cancer Patients Undergoing Radical Prostatectomy

MP61-12 WHICH MEN WITH CN1 PROSTATE CANCER AT PSMA PET/CT REPRESENT THE IDEAL CANDIDATE TO RADICAL PROSTATECTOMY? DEVELOPMENT OF A NOVEL RISK STRATIFICATION TOOL FOR INDIVIDUALIZED APPROACHES BASED ON A LARGE, MULTI-INSTITUTIONAL SERIES

The Prognostic Impact of Preoperative Psma-Pet on Early Oncological Outcomes in Prostate Cancer Patients Treated with Radical Prostatectomy: Results of a Multi-Center Analysis

Identifying the Optimal Candidates for a Super-Extended Staging Pelvic Lymph-Node Dissection in Prostate Cancer Patients Treated in the PET-PSMA Era. Results from a Multi-Institutional Series

Can We Rely on Available Models to Identify Candidates for Extended Pelvic Lymph Node Dissection (eplnd) in Men Staged with PSMA-PET? External Validation of the Briganti Nomograms and Development of a Novel Tool to Identify Optimal Candidates for Eplnd

External Validation of the Available Nomograms for the Identification of Candidates for a Staging Extended Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy in Prostate Cancer Patients Preoperatively Staged with PSMA PET

Improving Prediction of Local Stage by PSMA-PET: Development of a Novel Integrated Tool for Extracapsular Extension and Seminal Vesicle Invasion Combining Clinical and Imaging Features in Localized Prostate Cancer

The Significant Added Value of Concomitant Systematic Prostate Biopsies in Addition to Targeted Sampling in Patients with Previous Negative Biopsies. Implications for Accurate Staging Predictions from a Large Multi-Institutional Series

Optimizing Detection and Prediction of Prostate Cancer after Positive MRI and Negative Biopsies

The Impact of Multiple Lesions in Prostate MRI – Insights from the YAU Prostate Cancer Group

Staging Accuracy and Prognostic Value of Prostate-Specific Membrane Antigen PET/CT Strongly Depends on Lymph Node Tumor Burden

Mpmri of the Prostate in Patients Carrying a High Clinical Risk of Prostate Cancer Diagnosis: is This Imaging Test Necessary for Diagnostic Purposes in This Subset of Patients?

When Does Systematic Biopsy Information Matter the Most? Identifying Independent Predictors of Disease Downgrading at Radical Prostatectomy in High Grade Prostate Cancer Based on a Large Multi-Institutional Series

Predictors of PSMA positivity at initial staging of prostate cancer.

Integrating Index Lesion Volume to Better Classify Men with Indolent Prostate Cancer among Patients with Intermediate Risk Disease. Results from a Large, Multi-Institutional Series

MP20-04 FEASIBILITY AND ACCURACY OF TRANSPERINEAL FREE-HAND MPMRI TARGETED PROSTATE BIOPSIES UNDER LOCAL ANESTHESIA: A MULTICENTER PROSPECTIVE COHORT OF 1,014 PATIENTS

Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET

Has the Introduction of Multiparametric Magnetic Resonance Imaging of the Prostate and Targeted Biopsies Led to a Risk of Overgrading of High Risk Prostate Cancer? Results from a Contemporary, Large Multi-Institutional Series

Pelvic lymph node mapping in prostate cancer: examining the impact of PSMA PET/CT on radiotherapy decision-making in patients with node-positive disease